US regulatory status: approved.
pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen drug portfolio — 41 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Bagsværd, JP HQ
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 4
- Drugs
- 41
- Patents
- 0
NovoThirteen pipeline
Portfolio lens on 41 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
NovoThirteen drug portfolio — 41 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to NovoThirteen in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
concizumab
Blood and blood forming organs (B02)US regulatory status: approved. Molecular target: Tissue factor pathway inhibitor.
- Target
- Tissue factor pathway inhibitor
- Mechanism
- Tissue factor pathway inhibitor inhibitor
-
US regulatory status: approved.
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to NovoThirteen in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
finerenone
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
US regulatory status: approved. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in NovoThirteen's portfolio.
-
hydroxycarbamide
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in NovoThirteen's portfolio. Molecular target: Ribonucleoside-diphosphate reductase RR1.
- Target
- Ribonucleoside-diphosphate reductase RR1
- Mechanism
- Ribonucleoside-diphosphate reductase RR1 inhibitor
-
US regulatory status: approved. Molecular target: Ribonucleoside-diphosphate reductase RR1.
- Target
- Ribonucleoside-diphosphate reductase RR1
- Mechanism
- Ribonucleoside-diphosphate reductase RR1 inhibitor
-
insulin aspart
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to NovoThirteen in public FDA and regional records.
-
insulin degludec
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to NovoThirteen in public FDA and regional records.
-
Development asset linked to NovoThirteen in public FDA and regional records.
-
insulin detemir
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin glargine
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin human
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin icodec
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to NovoThirteen in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to NovoThirteen in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
liraglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to NovoThirteen in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
Development asset linked to NovoThirteen in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
semaglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
US regulatory status: approved.
-
somapacitan
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in NovoThirteen's portfolio. Molecular target: Growth hormone receptor.
- Target
- Growth hormone receptor
- Mechanism
- Growth hormone receptor agonist
-
somatropin
Systemic hormonal preparations (H01)US regulatory status: approved. Molecular target: Growth hormone receptor.
- Target
- Growth hormone receptor
- Mechanism
- Growth hormone receptor agonist
-
tirzepatide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Gastric inhibitory polypeptide receptor.
- Target
- Gastric inhibitory polypeptide receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist